Intralesional injection of 3 to 5 mL of 7.5 mg/mL cidofovir under general anesthesia is biweekly performed three times.
Sponsors
Kanazawa University
Conditions
recurrent respiratory papillomatosis
Unknown Phase
Efficacy and safety of cidofovir for recurrent respiratory papillomatosis (2)
Active, not recruitingJPRN-UMIN000020343
Start: 2012-04-26Target: 2Updated: 2026-06-29
Efficacy and safety of cidofovir for laryngeal papillomatosis (4)
Active, not recruitingJPRN-UMIN000020349
Start: 2013-10-01Target: 2Updated: 2026-06-29
Efficacy and safety of cidofovir for recurrent respiratory papillomatosis (1)
Active, not recruitingJPRN-UMIN000020342
Start: 2011-08-11Target: 2Updated: 2026-06-29
Efficacy and safety of cidofovir for laryngeal papillomatosis
Active, not recruitingJPRN-UMIN000020350
Start: 2014-03-03Target: 20Updated: 2026-06-29
Efficacy and safety of cidofovir for recurrent respiratory papillomatosis (3)
Active, not recruitingJPRN-UMIN000020348
Start: 2012-10-25Target: 1Updated: 2026-06-29